Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216734 | 0.75 | KDM4E (0.62) | KDM4EALDH1A1RAB9AHPGDNPC1 | |
| SCHEMBL14395935 | 0.73 | KDM4E (0.51) | KDM4EALDH1A1RAB9AHPGDNPC1 | |
| SCHEMBL14395878 | 0.72 | KDM4E (0.50) | KDM4EALDH1A1RAB9AHPGDNPC1 | |
| SCHEMBL8244239 | 0.71 | KDM4E (0.62) | KDM4EALDH1A1RAB9AHPGDNPC1 | |
| SCHEMBL4211785 | 0.71 | KDM4E (0.53) | KDM4EALDH1A1RAB9AHPGDNPC1 | |
| SCHEMBL6395252 | 0.69 | KDM4E (0.55) | KDM4EALDH1A1RAB9AHPGDNPC1 | |
| SCHEMBL16198921 | 0.69 | KDM4E (0.70) | KDM4EALDH1A1RAB9AHPGDNPC1 | |
| SCHEMBL16659332 | 0.69 | KDM4E (0.70) | KDM4EALDH1A1RAB9AHPGDNPC1 | |
| SCHEMBL13473838 | 0.69 | KDM4E (0.55) | KDM4EALDH1A1RAB9AHPGDNPC1 | |
| SCHEMBL16659334 | 0.69 | KDM4E (0.70) | KDM4EALDH1A1RAB9AHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066006-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLYCOMIMETICS, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9867841-B2 | Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells | GLYCOMIMETICS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9796745-B2 | E-selectin antagonist compounds, compositions, and methods of use | GLYCOMIMETICS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160289257-A1 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV | GLYCOMIMETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160184339-A1 | Compounds, Compositions and Methods Using E-Selectin Antagonists for Mobilization of Hematopoietic Cells | GLYCOMIMETICS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160145290-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLYCOMIMETICS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9109002-B2 | E-selectin antagonist compounds, compositions, and methods of use | GLYCOMIMETICS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150110808-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLYCOMIMETICS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-RE44778-E1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8633303-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130261070-A1 | ANTI-EPILEPTOGENIC AGENTS | GLYCOMIMETICS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130184229-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8361975-B2 | Compounds and methods for treatment of sickle cell or complications associated therewith | GLYCOMIMETICS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120015898-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SICKLE CELL DISEASE OR COMPLICATIONS ASSOCIATED THEREWITH | GLYCOMIMETICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110257380-A1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110251148-A1 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV | GLYCOMIMETICS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184229-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | KDM4E 4573/4885ALDH1A1 524/4885RAB9A 1655/4885 |
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | KDM4E 4593/4885ALDH1A1 679/4885RAB9A 1809/4885 |
| US-20160289257-A1 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV | SIGLEC9, FUT5, FUT6 | KDM4E 3149/4885ALDH1A1 3564/4885RAB9A 2334/4885 |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | KDM4E 4593/4885ALDH1A1 679/4885RAB9A 1809/4885 |
| US-20110251148-A1 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV | SIGLEC9, FUT5, FUT6 | KDM4E 3149/4885ALDH1A1 3564/4885RAB9A 2334/4885 |
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, ENGASE, FUT5 | KDM4E 4548/4885ALDH1A1 2041/4885RAB9A 3884/4885 |
| US-20180066006-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SELE, SELPLG, SELP | KDM4E 3628/4885ALDH1A1 3541/4885RAB9A 2907/4885 |
| US-20160145290-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SELE, SELPLG, SELP | KDM4E 3628/4885ALDH1A1 3744/4885RAB9A 2851/4885 |
| US-20120015898-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SICKLE CELL DISEASE OR COMPLICATIONS ASSOCIATED THEREWITH | HBG1, HBG2, SORD | KDM4E 4247/4885ALDH1A1 249/4885RAB9A 2448/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | KDM4E 4593/4885ALDH1A1 679/4885RAB9A 1809/4885 |
| US-20150110808-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SELE, SELPLG, SELP | KDM4E 3628/4885ALDH1A1 3541/4885RAB9A 2907/4885 |
| US-20130261070-A1 | ANTI-EPILEPTOGENIC AGENTS | GAP43, PYGB, NLN | KDM4E 3871/4885ALDH1A1 1199/4885RAB9A 3909/4885 |
| US-20110257380-A1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, B3GNT2, FUT5 | KDM4E 4414/4885ALDH1A1 2000/4885RAB9A 3760/4885 |
| US-20160184339-A1 | Compounds, Compositions and Methods Using E-Selectin Antagonists for Mobilization of Hematopoietic Cells | SELE, SELP, SELPLG | KDM4E 4303/4885ALDH1A1 3152/4885RAB9A 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.